Harmonization of quality of care in an IBD center impacts disease outcomes: Importance of structure, process indicators and rapid access clinic. Issue 3 (March 2019)

• Record Type: Journal Article
• Authors: Reinglas, Jason; Restellini, Sophie; Gonczi, Lorant; Kurti, Zsuzsanna; Verdon, Christine; Nene, Sofia; Kohen, Rita; Afif, Waqqas; Bessissow, Talat; Wild, Gary; Seidman, Ernest; Bitton, Alain; Lakatos, Peter L.
• Is Part Of: Digestive and liver disease. Volume 51:Issue 3(2019)
• Page Start: 340
• Page End: 345
• Publication Date: 2019-03
• Subjects: Crohn's disease -- Quality indicators -- Quality of care -- Ulcerative colitis; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; 616.33005
• DOI: 10.1016/j.dld.2018.11.013
• Languages: English
• ISSNs: 1590-8658

Abstract

Abstract: Background and aims: We aimed to evaluate the quality of care at a tertiary inflammatory bowel disease (IBD) center using quality of care indicators (QIs) including patient assessment strategy, monitoring, treatment decisions and outcomes. Methods: We retrospectively reviewed the quality of care pre- and post-referral and during follow-up at the at the McGill University Health Center (MUHC) IBD center. Consecutive patients were included presenting with an outpatient visit ('index visit') between July and December 2016. Disease characteristics, biochemistry, imaging and endoscopy data, changes in medications, and vaccination profiles were captured. Results: 1357 patients were included. At referral, a large proportion of patients were objectively re-evaluated (ileocolonoscopy: 79%, cross-sectional imaging: 39.3%, biomarkers: 89.9%, 81.9%). Therapeutic strategy was changed in 53.6% with 22.5% of patients starting biologics. Tight objective patient monitoring was applied during follow-up (colonoscopy: 79%, cross-sectional imaging: 61.8% were available at index visit; C-reactive protein: 78%, Faecal calprotectin: 37.6%, therapeutic drug monitoring: 16.3% were performed additionally). Maximum therapeutic step was biologicals in 48.8% of the patients, while only 6.6% of all patients were steroid dependent. Implementation of a rapid access clinic improved healthcare delivery. Conclusions: Our data support that tight monitoring was applied at the MUHC IBD center with a high emphasis on objective patient (re)evaluation, timely access and accelerated treatment strategy at referral and during follow-up.